Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [HEALTH]
12 clusters · 71 sources · 59 days · First seen · Last updated
Indian Supreme Court litigation over medicine pricing
Overview
Advocate Ashwini Upadhyay filed a Public Interest Litigation (PIL) in the Supreme Court of India seeking a uniform national framework to address the manufacture and sale of counterfeit and adulterated medicines. The petition, prompted by reports of a racket in Karnataka involving fake cancer drugs and critical-care injections, called for stricter penalties, including the confiscation of assets from manufacturers and financiers. Subsequently, the Supreme Court declined to adjudicate the petition, instead forwarding it to the government as a representation for consideration. The Supreme Court has since shifted focus toward pharmaceutical pricing disparities. A bench expressed severe concern over the massive gap between supply prices and maximum retail prices (MRP), describing the situation as ‘carnage’. The court highlighted instances where cancer drugs supplied to retailers for approximately Rs 2,700 carried an MRP of Rs 27,000, and flagged practices by corporate hospitals that mandate the use of in-house pharmacies. In response, the National Pharmaceutical Pricing Authority (NPPA) implemented a Trade Margin Rationalisation (TMR) measure to cap margins at 30% for 137 non-scheduled anti-cancer drugs. As of November 9, 2026, revised prices for 1,364 anti-cancer drug formulations have come into effect. Following the implementation, 85 pharmaceutical companies reported revised MRPs covering 121 drugs. Of these, 679 brands reported price reductions exceeding 50 percent, with the highest reduction reaching 96.45 percent. For instance, the breast cancer treatment capsule ‘Palpro’ reportedly dropped from Rs 40,421.33 to Rs 2,720. The Ministry of Chemicals and Fertilizers estimates these reductions will save consumers approximately Rs 3,540.38 crore annually. To ensure compliance, the NPPA has ordered strict monitoring of the trade margin rationalisation for these 137 drugs. Manufacturers, stockists, and medical institutions must prominently display updated price lists.
Entities
National Pharmaceutical Pricing Authority · India · Department of Pharmaceuticals · Supreme Court of India · Ministry of Chemicals and Fertilizers
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 13 SOURCES] The revised MRPs for the 543 anti-cancer medicine brands will be effective from November 9, 2026.
- [● 14 SOURCES] The NPPA revised the MRP for 543 brands of anti-cancer medicines.
- [● 11 SOURCES] A cancer drug with a price to retailer (PTR) of approximately Rs 2,700 to Rs 3,000 has a maximum retail price (MRP) of Rs 27,000.
- [● 11 SOURCES] The court flagged the practice of corporate hospitals requiring patients to use in-house pharmacies.
- [● 10 SOURCES] The court questioned why a uniform 16 percent margin cap is not applied to all pharmaceutical products.
- [● 9 SOURCES] The NPPA has capped trade margins for 137 non-scheduled anti-cancer drugs at 30% of the Maximum Retail Price (MRP).
- [● 9 SOURCES] The price of the 137 identified drugs is expected to decrease by up to 70%.
- [● 9 SOURCES] The Supreme Court of India reserved its verdict on petitions regarding medicine pricing and regulation.
- [● 9 SOURCES] The NPPA capped trade margins on 137 anti-cancer drugs at 30 percent.
- [● 9 SOURCES] The highest reported price reduction is 96.45 percent.
- [● 8 SOURCES] The court questioned the distinction between essential and non-essential medicines under the Drug Price Control Order (DPCO).
Timeline
-
[BUSINESS] 7 sourcesIndia NPPA mandates strict monitoring of 137 anti-cancer drug prices
India's NPPA has ordered strict monitoring of 137 anti-cancer drugs following a 30 per cent cap on trade margins to ensure lower prices are passed to patients.
-
[HEALTH] 2 sourcesIndia implements major price cuts for cancer medications
India has slashed the cost of nearly 1,300 cancer drug brands by up to 96 percent, a reform expected to save patients approximately 2.59 billion euros annually.
-
[HEALTH] 11 sourcesIndia implements price cuts for 1,364 anti-cancer drugs
India has slashed prices for 1,364 anti-cancer drugs by up to 96.45 percent, aiming to save consumers Rs 3,540 crore annually through capped trade margins.
-
[HEALTH] 13 sourcesIndia caps trade margins on 137 anti-cancer drugs to reduce costs
India's NPPA has capped trade margins on 137 anti-cancer drugs, effective November 9, aiming to save patients approximately Rs 3,502 crore annually through significant price reductions.
-
[BUSINESS] 5 sourcesNPPA revises prices for 543 brands of anti-cancer drugs in India
India's NPPA has revised prices for 543 anti-cancer drug brands, effective November 9, 2026, capping trade margins for 137 non-scheduled medicines to improve patient affordability.
-
[BUSINESS] 25 sourcesIndia NPPA revises prices for 543 anti-cancer drug brands
India's NPPA has slashed prices for 543 anti-cancer drug brands by up to 93.3% following a trade margin cap. The new rates take effect November 9, 2026, though many patented drugs remain unchanged.
-
[HEALTH] 6 sourcesIndia proposes 30% trade margin cap on cancer drugs
The Indian government proposes capping trade margins on non-scheduled cancer drugs at 30% of MRP to curb excessive hospital mark-ups and save patients an estimated ₹2,500 crore annually.
-
[HEALTH] 2 sourcesIndia to reduce prices of 137 cancer medicines by up to 70%
India will slash prices of 137 cancer medicines by up to 70% starting November 9, 2026, after the NPPA capped trade margins at 30% to improve treatment accessibility.
-
[HEALTH] 13 sourcesNPPA caps trade margins on 137 anti-cancer drugs in India
India's NPPA has capped trade margins at 30% for 137 non-scheduled anti-cancer drugs, potentially reducing prices by up to 70% starting November 9, 2026, to improve treatment affordability.
-
[POLITICS] 9 sourcesIndia to cap trade margins on cancer drugs amid Supreme Court scrutiny
The Indian government will cap trade margins on certain cancer drugs at 30% of MRP, though the Supreme Court has urged a broader review of excessive markups on all medicines and medical devices.
-
[POLITICS] 14 sourcesSupreme Court slams massive markups on cancer drugs
The Supreme Court of India has slammed the massive markups on cancer drugs, calling the price disparity ‘carnage’ and questioning the need for a uniform 16% margin cap on all medicines.
-
[HEALTH] 4 sourcesSupreme Court PIL seeks national framework to combat fake medicines
A PIL in the Indian Supreme Court seeks a national framework to tackle fake and adulterated medicines, demanding time-bound trials and asset confiscation following reports of counterfeit drug rackets.
Sources
aajtak.com · agniban.com · avnews.in · bhaskarhindi.com · bhaskarlive.in · bilkulonline.com · cargoinsights.co · chennaionline.com · chennaivision.com · cinemaskope.com.br · deccanchronicle.com · desitalkchicago.com · devdiscourse.com · disabledperson.com · dtnext.in · ehealth.eletsonline.com · en.etemaaddaily.com · english.mathrubhumi.com · english.publictv.in · expresspharma.in · freshheadline.com · highlandpost.com · hindi.asianetnews.com · india.com · kannada.asianetnews.com · khabarpahad.com · kreiszeitung.de · kurierverlag.de · lagatar24.com · lawchakra.in · madhyamamonline.com · malaimurasu.com · medgatetoday.com · medicaldialogues.in · millenniumpost.in · montagehotels.com · morungexpress.com · mpbreakingnews.in · navabharat.com · navbharatlive.com · newindianexpress.com · news.abplive.com · news18.com · news9live.com · newsable.asianetnews.com · newsindialive.in · newstodaynet.com · newswire.lk
This summary has been updated 22 times: see revision history